Try our Advanced Search for more refined results

Novartis Pharmaceuticals Corporation, Petitioner v. HEC Pharm Co., Ltd., et al.

  1. April 17, 2023

    Justices Won't Take Up Novartis-HEC Feud Over MS Drug

    The U.S. Supreme Court on Monday rebuffed Novartis Pharmaceuticals' call for it to review a Federal Circuit ruling that invalidated the drugmaker's patent on blockbuster multiple sclerosis treatment Gilenya.

  2. March 03, 2023

    HEC Says Axed Novartis Patent Win 'Not Remotely Certworthy'

    Chinese pharmaceutical company HEC Pharm told the U.S. Supreme Court Friday that a Federal Circuit opinion invalidating Novartis Pharmaceuticals' patent on multiple sclerosis drug Gilenya is "not remotely certworthy," arguing that Novartis is just trying to milk its monopoly on the treatment.

  3. February 22, 2023

    Ex-Judges Slam Panel Swap That Sunk Novartis Patent Win

    Five retired federal appeals court judges have told the U.S. Supreme Court that the Federal Circuit wrongly turned a patent win for Novartis into a loss by replacing a retired judge on the panel during a rehearing, saying the case threatens faith in the courts.

  4. January 23, 2023

    Novartis Tells Justices Judge Swap Wrongly Sunk Patent Win

    Novartis Pharmaceuticals has urged the U.S. Supreme Court to undo a Federal Circuit ruling invalidating a patent on blockbuster multiple sclerosis drug Gilenya, saying the appellate court incorrectly backed out of a decision upholding the patent after a panel change.